Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages

  Langone, Phyllis ^a   Debata, Priya Ranjan ^a   Dolai, Sukanta ^a   Curcio, Gina Marie ^a   Inigo, Joseph Del Rosario ^a   Raja, Krishnaswami ^a   Banerjee, Probal ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Akt 1; brain tumor; cancer; curcumin; NF kB; targeting

Indexed keywords

2,5 DIOXYCYCLOPENTYL 4 [7 (4 HYDROXY 3 METHOXYPHENYL) 3,5 DIOXOHEPTA 1,6 DIENYL] 2 METHOXYPHENYL GLUTARATE; 5 [4 [7 (4 HYDROXY 3 METHOXYPHENYL) 3,5 DIOXOHEPTA 1,6 DIENYL] 2 METHOXYPHENOXY] 5 OXOPENTANOIC ACID; CARBOXYLIC ACID DERIVATIVE; CASPASE 3; CASPASE 7; CD146 ANTIGEN; CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTIBODIES, NEOPLASM; BRAIN NEOPLASMS; CURCUMIN; IMMUNOCONJUGATES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

EID: 84862551554     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26479     Document Type: Article

References (49)

1. Kunnumakkara AB, Anand P, Aggarwal BB,. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
2. Lopez-Lazaro M,. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 2008; 53: S103-27.
3. Steward WP, Gescher AJ,. Curcumin in cancer management: recent results of analyogue design and clinical studies and desirable future research. Mol Nutr Food Res 2008; 52: 1005-9.
4. Calabrese V, Bates TE, Mancuso C, Cornelius C, Ventimiglia B, Cambria MT, Di Renzo L, De Lorenzo A, Dinkova-Kostova AT,. Curcumin and cellular stress response in free radical-related diseases. Mol Nutr Food Res 2008; 52: 1062-73.
5. Sharma RA, Gescher AJ, Steward WP,. Curcumin: the story so far. Eur J Cancer 2005; 41: 1955-68. (Pubitemid 41557681)
6. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res. 2001; 21: 2895-900.
7. Deodhar SD, Sethi R, Srimal RC,. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Ind J Med Res 1980; 71: 632-4. (Pubitemid 10058826)
8. Burgos-Morõn E, Calderõn-Montaño JM, Salvador J, Robles A, Lõpez-Lázaro, M., The dark side of curcumin. Int J Cancer 2010; 126: 1771-5.
9. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, et al. Phase I clinical trial of oral curcumin. Clin Cancer Res 2004; 10: 6847-54.
10. Tran B, Rosenthal MA,. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 2010; 17: 417-21.
11. Tse V,. Brain metastasis. Available at:. Accessed Nov 10, 2009.
12. Walbert R, Gilbert MR,. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 2009; 14: 229-306.
13. Varlotto JM, Flickinger JC, Niranian A, Bhatnagar AK, Kondziolka D, Lundsford LD,. Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2003; 57: 452-64. (Pubitemid 37040942)
14. Aggarwal BB, Sung B,. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009; 30: 85-94.
15. Dempe JS, Pfeiffer E, Grimm AS, Metzler M,. Metabolism of curcumin and induction of mitotic catastrophe in human cancer cells. Mol Nutr Food Res 2008; 52: 1074-81.
16. Kurien BT, Scofield RH,. Heat-solubilized curcumin should be considered in clinical trials for increasing bioavailability. Clin Cancer Res 2009; 15: 747.
17. Kurien BT, Scofield RH,. Curcumin/turmeric solubilized in sodium hydroxide inhibits HNE protein modification-an in vitro study. J Ethnopharmacol 2007; 110: 368-73. (Pubitemid 46283670)
18. Aggarwal BB,. Response to Kurien and Scofield: solubility and bioavailability of curcumin. Trends Pharmacol Sci 2009; 30: 335.
19. Purkayastha S, Berliner A, Fernando SS, Ranasinghe B, Ray I, Tariq H, Banerjee P,. Curcumin blocks brain tumor formation. Brain Res 2009; 1266C: 130-8.
20. Shi W, Dolai S, Rizk S, Hussain A, Tariq H, Averick S, L'Amoreaux W, El-Idrissi A, Banerjee P, Raja K,. Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a PAMAM dendrimer curcumin conjugate for therapeutic applications. Org Lett 2007; 9: 5461-4.
21. Cline GW, Hanna SB,. The aminolysis of N-hydroxysuccinimide esters. A structure-reactivity study. J Am Chem Soc 1987; 109: 3087-91.
22. Hermanson GT,. Tags and probes bioconjugate techniquesed. San Diego, CA: Academic Press, 1996. 306 p.
23. Raja KS, Wang Q, Gonzalez J, Manchester M, Johnson JE, Finn MG,. Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 2003; 4: 472-6. (Pubitemid 36701213)
24. Paxinos G, Franklin KBJ,. The mouse brain in stereotaxic coordinates, 2nd edn. New York: Academic Press, 2001.
25. Ross L, Barclay C, Vinquist R, Mukai K, Goto H, Hashimoto Y, Tokunaga A, Uno H,. On the antioxidant mechanism of curcumin: classical methods are needed to determine antioxidant mechanism and activity. Org Lett 2000; 2: 2841-3.
26. Wright JS,. Predicting the antioxidant activity of curcumin and curcuminoids. THEOCHEM 2002; 91: 207-17.
27. Simon A, Allais DP, Duroux JL, Basly JP, Durand-Fontanier S, Delage C,. Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships. Cancer Lett 1998; 129: 111-6. (Pubitemid 28375245)
28. Shen L, Ji H-F,. Theoretical study on physicochemical properties of curcumin. Spectrochim Acta Part A 2007; 67: 619-23. (Pubitemid 46809631)
29. Payton F, Sandusky P, Alworth WL,. NMR study of the solution structure of curcumin. J Nat Product 2007; 70: 143-6. (Pubitemid 46447622)
30. Lehmann JM, Riethmuller G, Johnson JP,. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1989; 86: 9891-5. (Pubitemid 20030740)
31. Schlagbauer-Wadl H, Jansen B, Müller M, Polterauer P, Wolff K, Eichler H-G, Pehamberger H, Konakand E, Johnson JP,. Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in SCID mice. Int J Cancer 1999; 81: 951-5. (Pubitemid 29249982)
32. Karin M, Cao Y, Greten FR, Li Z-W,. NH-kB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-10. (Pubitemid 37328783)
33. Meng F, Liu L, Chin PC, D'Mello SR,. Akt is a downstream target of NF-kB. J Biol Chem 2002; 277: 29674-80.
34. Schrama D, Reisfeld RA,. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5: 147-59.
35. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448: 439-44. (Pubitemid 47123510)
36. Dunlap JL, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL, Troxell ML,. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 2010; 120: 409-18.
37. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS, Jr., NF-kappa B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19: 5785-99. (Pubitemid 29339933)
38. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M,. NF-kappa B function in growth control: regulation of Cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999; 19: 2690-8. (Pubitemid 29144513)
39. Dance-Barnes ST, Kock ND, Moore JE, Lin EY, Mosley LJ, D'Agostino RB, Jr, McCoy TP, Townsend AJ, Miller MS,. Lung tumor promotion by curcumin. Carcinogenesis 2009; 30: 1016-23.
40. Fang J, Lu J, Holmgren A,. Thioredoxin reductase is irreversibly modified by curcumin. J Biol Chem 2005; 280: 25284-90.
41. Tamura T, Stadtman TC,. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc Natl Acad Sci 1996; 93: 1006-11. (Pubitemid 26054364)
42. Gladyshev VN, Jeang KT, Stadtman TC,. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci 1996; 93: 6146-51. (Pubitemid 26190818)
43. Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G,. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 2002; 512: 334-40. (Pubitemid 34164505)
44. Liontas A, Yeger, H., Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res 2004; 24: 987-98. (Pubitemid 38625049)
45. Tsvetkov P, Asher G, Reiss V, Shaul Y, Sachs L, Lotem J,. Inhibition of NAD(P)H: quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci USA 2005; 102: 5535-40. (Pubitemid 40530293)
46. Moos PJ, Edes K, Mullally JE, Fitzpatrick FA,. Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 2004; 25: 1611-7. (Pubitemid 39214303)
47. Martín-Cordero C, Lõpez-Lázaro M, Gálvez M, Jesús Ayuso M,. Curcumin as a DNA topoisomerase II poison. J Enzyme Inhibition Med Chem 2003; 18: 505-9.
48. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M,. Glutamata release promotes growth of malignant gliomas. Nat Med 2001; 7: 1010-5. (Pubitemid 32937380)
49. Grondin R, Zhang Z, Ai Y, Gash DM, Gerhardt GA,. Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog Drug Res 2003; 61: 101-23. (Pubitemid 37187404)